CognitrexCancerDigest

South Asia's first proton therapy centre was launched in Chennai on Friday. Apollo Proton Cancer Centre, equipped with the path-breaking pencil beam technology, offers hope to cancer patients from India and abroad. The centre was inaugurated by Vice President Venkaiah Naidu in the presence Tamil Nadu Chief Minister Edappadi K. Palaniswami and Apollo Hospitals Group chairman Dr Prathap C. Reddy. Speaking on the occasion, Naidu said, ''Cancer is a leading cause of death worldwide and is a major cause of mortality in India. Proton therapy, which is a pioneering treatment, has marked a new milestone in the medical journey of our country.'' ''It is pertinent to note that even a first world country like the UK launched a Proton Beam centre just last month, in December 2018, making our achievement in bringing this best and latest medical technology to India truly praiseworthy,'' said Reddy. ''It is with a sense of pride that we dedicate the Apollo

Drug maker Lupin is in the process of developing a pipeline of products under its new drug discovery programme to treat various diseases like cancer and metabolic disorders, a top company official said.  The company, which last month inked a partnership with global pharma company AbbVie for the development and commercialisation of its novel oncology drug to treat hematological cancers, is focussing on first-to-market kind of opportunities with its new products.  "The Novel Drug Discovery and Development (NDDD) is focused and committed on developing a pipeline of highly differentiated and innovative new chemical entities in various therapeutic areas like oncology, immunology and metabolic disorders," Lupin President NDDD Raj Kamboj told PTI.  When asked about company’s ambitions from the programme over the next two-three years, he said, "Lupin will focus NDDD activities to advance pipeline programs where there are first-to-market and/or best-in-class opportunities. Em

Aurobindo Pharma is focussing on building a diverse speciality portfolio of nearly 150 products with an addressable market size of USD 118.2 billion in the next three financial years, the drug firm said in an investor presentation on Monday. The speciality portfolio will be in various therapeutic segments such as oncology and hormones, biologics, topicals, nasals, peptides, depot injection, inhalers, vaccines and transdermal patches totalling 147 products under development. In a regulatory filing to BSE, the company said 79 products are under development in oncology and hormones, 22 are in topicals, 5 are in nasals, 14 are in peptides and 4 in depot injection segment. The other products under development are 8 in transdermal patches, 8 in inhalers, 6 in biologics and one in vaccines, it added. While largest addressable market size is USD 45 billion for oncology and hormones segment, it is USD 35 billion for biologics and USD 12.2 billion for peptides segment, the presentation sai